JewishStatusOpen the app

Jewish News 24 · Nov 20, 2026

Jewish News 24 — photo status

💊 NEW PANCREATIC CANCER DATA: DARAXONRASIB PLUS CHEMO SHOWS PROMISE: In an early-phase trial of 61 patients with previously untreated metastatic pancreatic cancer, the pill daraxonrasib combined with chemotherapy controlled disease in about 90% of patients, shrank tumors in about 61% and produced complete responses in 8%. Median progression-free survival was 12.8 months, the company said at a cancer conference. Separately, in a larger phase 3 trial of previously treated patients, those on daraxonrasib survived a median of 13.2 months versus 6.7 months on chemotherapy. The FDA approved the once-daily pill in August for previously treated metastatic pancreatic cancer; the combination is not yet approved. Researchers call the findings encouraging, but the treatment isn't a cure.

💊 NEW PANCREATIC CANCER DATA: DARAXONRASIB PLUS CHEMO SHOWS PROMISE: In an early-phase trial of 61 patients with previously untreated metastatic pancreatic cancer, the pill daraxonrasib combined with chemotherapy controlled disease in about 90% of patients, shrank tumors in about 61% and produced complete responses in 8%. Median progression-free survival was 12.8 months, the company said at a cancer conference. Separately, in a larger phase 3 trial of previously treated patients, those on daraxonrasib survived a median of 13.2 months versus 6.7 months on chemotherapy. The FDA approved the once-daily pill in August for previously treated metastatic pancreatic cancer; the combination is not yet approved. Researchers call the findings encouraging, but the treatment isn't a cure.

Watch in the app All of Jewish News 24's statuses

More from Jewish News 24